Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KDTV001 for cervical HSIL (HPV16/18/52+)
CTR20254828Phase 2Active
- Sponsor
- KDGene
- Start
- Jan 2026
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of KDTV001 in cervical intraepithelial neoplasia (CIN), HPV16 infection (HPV16) and human papillomavirus infection, sponsored by KDGene. Primary endpoints: Incidence and severity of serious adverse events (SAEs) and adverse events (AEs) – Phase I, Cellular immune response to HPV16/18/52 E6/E7 – Phase I and 4 more. Started Jan 2026; status: active.
02
Drugs
KDTV001
03
Conditions
cervical intraepithelial neoplasia (CIN)HPV16 infection (HPV16)human papillomavirus infection
Beyond the preview
Go deeper on CTR20254828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254828.